Position in BCYC
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$6,733
-$12,838 QoQ
Shares Held
1,588
-62.4% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#88
of 103 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ASSETMARK, INC holds $347,870,603 across 93 Biotechnology names. BCYC ranks #63 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
3,433,824 | $186,834,363 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
61,055 | $30,327,850 | |
| 3 | DFTX |
Definium Therapeutics, Inc.
|
396,542 | $18,653,335 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
174,334 | $13,645,122 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
98,687 | $12,097,052 | |
| 6 | ONC |
BeOne Medicines Ltd.
|
32,399 | $9,232,743 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
12,594 | $7,852,862 | |
| 8 | ARGX |
Argenx SE
|
7,699 | $7,142,901 |
All Filings in BCYC
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,733 | 1,588 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $19,571 | 4,218 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $25,686 | 3,628 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $28,057 | 3,625 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $14,407 | 2,073 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $10,884 | 1,282 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $17,640 | 1,260 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $34,374 | 1,519 | Shares | Sole | 2024-11-01 | |
| No filing history on record for this holder in this stock. | ||||||